Results 141 to 150 of about 598,741 (306)

Progress of Microsatellite (GT/CA)n Repeat Polymorphisms in Non-small Cell Lung Cancer

open access: yesZhongliu Fangzhi Yanjiu
Non-small cell lung cancer (NSCLC) is the most important histological type of lung cancer. This disease affects a large number of patients, and the prognosis of advanced patients is poor.
YANG Wenjun   +4 more
doaj   +1 more source

DSG2+ Cancer Stem Cells Co‐Located With FAP+ Myofibroblasts in the Tumor Boundary That Determines the Efficacy of Immunotherapy in Non‐Small Cell Lung Cancer

open access: yesAdvanced Science, EarlyView.
Cancer stem cells (CSCs) in non‐small cell lung cancer display pronounced plasticity and spatial heterogeneity. By integrating single‐cell and spatial transcriptomics, this study defines a DSG2‐associated CSC program and reveals a tumor‐margin niche formed with FAP+ myofibroblasts.
Guangyu Fan   +8 more
wiley   +1 more source

Pancreatic Adenocarcinoma with Co-Occurrence of KRAS and EGFR Mutations: Case Report and Literature Review

open access: yesCase Reports in Oncology
Introduction: Mutation in Kristin ras sarcoma virus (KRAS) oncogene is the main driver in pancreatic ductal adenocarcinoma (PDAC) and is present in nearly 90% of patients with PDAC.
Juhi Mody, Mandana Kamgar
doaj   +1 more source

NPM1 Mediates mRNA Sorting into Extracellular Vesicles via Specific RNA Motif Binding and Phase Separation

open access: yesAdvanced Science, EarlyView.
NPM1 selectively sorts specific mRNAs into extracellular vesicles (EVs) by recognizing RNA motifs and forming phase‐separated condensates. These mRNA cargos—including EGFR—are then loaded via multivesicular bodies. This active sorting pathway, validated in EVs derived from both lung cancer cells and patient serum, reveals a specific mechanism for ...
Kaixiang Zhang   +8 more
wiley   +1 more source

Cuproptosis and Disulfidptosis Converge to Empower PD‐L1 Checkpoint Therapy via Cadict‐Induced PD‐L1 Translation

open access: yesAdvanced Science, EarlyView.
This study introduces Cadict, an EGFR‐targeted nanodrug that co‐delivers cuproptosis and disulfidptosis inducers to overcome immune resistance. Cadict synergistically enhances tumor cytotoxicity and sensitizes cancers to ICIs by upregulating PD‐L1 via an Eif5b‐dependent translation mechanism, fostering a potent antitumor immune response and ...
Shaoqing Huang   +12 more
wiley   +1 more source

cDC1 Subtype‐Specific In Vivo Targeting of Liposomes

open access: yesAdvanced Science, EarlyView.
Dendritic cells, particularly the cDC1 subtype, offer a promising target for drug delivery via liposomes due to their pivotal role in immune regulation, allowing for amplified therapeutic responses. Herein, we show an integration of physicochemical characterization and cell experiments to achieve effective in vivo cDC1 targeting through anti‐CLEC9A ...
Maximilian Schaaf   +11 more
wiley   +1 more source

Understanding and Overcoming Antibody‐Drug Conjugate Resistance: Biological Mechanisms and Emerging Analytical Frameworks in Breast Cancer

open access: yesAdvanced Science, EarlyView.
Antibody–drug conjugates (ADCs) transform breast cancer therapy, yet resistance limits their durability. Emerging evidence reveals that ADC failure is not solely tumor‐intrinsic but shaped by dynamic tumor–microenvironment interactions that alter drug delivery, processing, and response.
Minji Seo, Jangsoon Lee, Naoto T. Ueno
wiley   +1 more source

Deciphering and Targeting the Schwannoma‐Neuron‐Macrophage Crosstalk for the Treatment of Schwannomatosis and Associated Pain

open access: yesAdvanced Science, EarlyView.
We established patient‐derived SWN cell lines and orthotopic PDX models that recapitulate patient pain phenotypes, alongside a novel intravital DRG imaging platform to track macrophage infiltration and neuronal pain responses. Using these models, we define HMGB1–CCL2–IL‐6 signaling crosstalk driving pain and identify EGF signaling as a key regulator of
Zhenzhen Yin   +17 more
wiley   +1 more source

EGFR Story

open access: yes, 2020
Presentation going through an analysis around the results of the osimertinib/gefitinib story.
openaire   +1 more source

Home - About - Disclaimer - Privacy